Roivant Sciences (ROIV) Competitors $12.00 +0.03 (+0.25%) (As of 11:52 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ROIV vs. BNTX, TEVA, BGNE, MRNA, VTRS, SMMT, GMAB, RDY, CTLT, and SRPTShould you be buying Roivant Sciences stock or one of its competitors? The main competitors of Roivant Sciences include BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Moderna (MRNA), Viatris (VTRS), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Catalent (CTLT), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical products" industry. Roivant Sciences vs. BioNTech Teva Pharmaceutical Industries BeiGene Moderna Viatris Summit Therapeutics Genmab A/S Dr. Reddy's Laboratories Catalent Sarepta Therapeutics Roivant Sciences (NASDAQ:ROIV) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends, valuation and community ranking. Do analysts rate ROIV or BNTX? Roivant Sciences presently has a consensus target price of $17.93, indicating a potential upside of 49.53%. BioNTech has a consensus target price of $140.76, indicating a potential upside of 24.45%. Given Roivant Sciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Roivant Sciences is more favorable than BioNTech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88BioNTech 0 Sell rating(s) 4 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.82 Which has more volatility and risk, ROIV or BNTX? Roivant Sciences has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500. Comparatively, BioNTech has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500. Which has stronger valuation & earnings, ROIV or BNTX? Roivant Sciences has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRoivant Sciences$124.79M69.94$4.35B$5.652.12BioNTech$3.04B8.84$1.01B-$2.10-53.86 Does the MarketBeat Community prefer ROIV or BNTX? BioNTech received 88 more outperform votes than Roivant Sciences when rated by MarketBeat users. However, 77.27% of users gave Roivant Sciences an outperform vote while only 45.87% of users gave BioNTech an outperform vote. CompanyUnderperformOutperformRoivant SciencesOutperform Votes5177.27% Underperform Votes1522.73% BioNTechOutperform Votes13945.87% Underperform Votes16454.13% Do institutionals and insiders hold more shares of ROIV or BNTX? 64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 7.9% of Roivant Sciences shares are owned by company insiders. Comparatively, 19.2% of BioNTech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media refer more to ROIV or BNTX? In the previous week, BioNTech had 2 more articles in the media than Roivant Sciences. MarketBeat recorded 8 mentions for BioNTech and 6 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.85 beat BioNTech's score of 0.27 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 0 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is ROIV or BNTX more profitable? Roivant Sciences has a net margin of 3,827.42% compared to BioNTech's net margin of -15.16%. BioNTech's return on equity of -2.35% beat Roivant Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Roivant Sciences3,827.42% -14.65% -13.19% BioNTech -15.16%-2.35%-2.05% SummaryRoivant Sciences beats BioNTech on 11 of the 19 factors compared between the two stocks. Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Get Roivant Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ROIV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ROIV vs. The Competition Export to ExcelMetricRoivant SciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.73B$6.66B$5.18B$9.21BDividend YieldN/A3.00%5.12%4.30%P/E Ratio2.1210.5787.6517.17Price / Sales69.94192.331,165.15121.16Price / CashN/A57.1643.2337.84Price / Book1.505.104.794.79Net Income$4.35B$151.58M$120.46M$225.43M7 Day Performance-1.32%-1.95%-0.97%-0.12%1 Month Performance-4.31%-4.27%15.25%1.56%1 Year Performance10.10%8.63%29.71%16.07% Roivant Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ROIVRoivant Sciences2.8812 of 5 stars$12.00+0.3%$17.93+49.4%+9.9%$8.74B$124.79M2.12860BNTXBioNTech2.0422 of 5 stars$113.30+0.2%$140.76+24.2%+7.8%$26.93B$3.04B-53.956,133TEVATeva Pharmaceutical Industries1.8954 of 5 stars$22.02-0.3%$20.88-5.2%+111.9%$24.95B$16.77B-25.9137,851Options VolumeBGNEBeiGene2.777 of 5 stars$177.01+0.3%$253.69+43.3%+0.9%$17.25B$3.32B-21.4810,600Positive NewsMRNAModerna4.2678 of 5 stars$39.23-0.4%$79.50+102.7%-58.3%$15.10B$5.06B-6.745,600VTRSViatris2.6118 of 5 stars$12.45-0.6%$13.67+9.8%+17.3%$14.86B$15.05B-16.8238,000News CoverageGap DownSMMTSummit Therapeutics3.2974 of 5 stars$18.62+4.2%$33.33+79.0%+687.8%$13.73B$700,000.00-66.50105Gap UpGMABGenmab A/S4.2496 of 5 stars$20.53+1.1%$45.20+120.2%-34.0%$13.59B$19.84B19.932,204Positive NewsRDYDr. Reddy's Laboratories1.1672 of 5 stars$15.41+0.3%$17.00+10.3%+15.0%$12.86B$299.87B24.6227,048CTLTCatalent2.5864 of 5 stars$63.48flat$63.40-0.1%N/A$11.52B$4.42B-28.0916,900SRPTSarepta Therapeutics4.7387 of 5 stars$120.25+1.1%$178.71+48.6%+27.6%$11.49B$1.64B96.201,314 Related Companies and Tools Related Companies BNTX Competitors TEVA Competitors BGNE Competitors MRNA Competitors VTRS Competitors SMMT Competitors GMAB Competitors RDY Competitors CTLT Competitors SRPT Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ROIV) was last updated on 12/24/2024 by MarketBeat.com Staff From Our Partners"This looks and feels like 2000," says investing legendOur senior analyst Dan Ferris says a new surprise crisis could begin at any moment... and this time, he says i...Stansberry Research | SponsoredA.I. Trading System Helps Some Traders Pocket $1,100 per DAY!What if I told you 60 seconds a day could completely change your life? This AI-powered trading syst...Prosper Trading Academy | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredWall St. Icon: “If you wait on this, it will already be too late”If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roivant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Roivant Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
